We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Positive Regulatory Updates Further Boost INCY Stock?
Read MoreHide Full Article
Key Takeaways
Jakafi continues to drive Incyte's revenues with solid sales momentum across all approved uses.
Opzelura's label expansion and strong uptake in atopic dermatitis and vitiligo boost top-line growth.
New approvals for Monjuvi and Zynyz strengthen Incyte's oncology portfolio and future revenue prospects.
Incyte (INCY - Free Report) has put up a stellar performance year to date on the back of better-than-expected quarterly results, and positive pipeline and regulatory updates.
INCY’s Lead Drug Jakafi Maintains Momentum
Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Sales in all indications continue to be strong and should maintain momentum going forward.
Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets. Incyte earns royalties from NVS on sales outside the country.
Opzelura Boosts INCY’s Top Line
The FDA’s approval of the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis (AD), under the brand name Opzelura, has been a significant boost for the company. The drug’s label was recently expanded for mild to moderate AD in non-immunocompromised children two years of age and older.
The drug is also approved for the topical treatment of non-segmental vitiligo in adult and pediatric patients aged 12 years and above. The approval makes Opzelura the first and only topical formulation of a JAK inhibitor approved in the United States. The uptake of Opzelura has been strong, driven by increased patient demand and refills in both atopic dermatitis and vitiligo.
Pipeline/Regulatory Updates Boost INCY Stock
Incyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.
Encouraging uptake of new drugs like Pemazyre, Monjuvi and Tabrecta also contributes to its top-line growth.
The FDA had earlier approved Monjuvi (tafasitamab-cxix) for a new cancer indication.
Monjuvi, in combination with Rituxan (rituximab) and Revlimid (lenalidomide), was approved for the treatment of adult patients with relapsed or refractory follicular lymphoma, a type of slow-growing blood cancer.
The drug is already approved, in combination with Revlimid, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
Incyte gained worldwide exclusive global rights for tafasitamab from MorphoSys AG in February 2024. Tafasitamab is marketed as Monjuvi in the United States and as Minjuvi in the ex-U.S. markets.
The label expansion of the drug should boost sales of the drug.
In May 2025, the FDA approved a label expansion of oncology drug Zynyz (retifanlimab-dlwr), a PD-1 inhibitor. The regulatory body has now approved Zynyz in combination with chemotherapy and as a single agent for the treatment of adult patients with advanced squamous cell carcinoma of the anal canal.
Zynyz is also indicated in the United States for the treatment of adult patients with metastatic or recurrent locally advanced merkel cell carcinoma.
Earlier, INCY’s new global collaboration with Qiagen (QGEN - Free Report) also impressed investors.
The collaboration is aimed at developing a novel diagnostic panel to support INCY’s pipeline of investigational treatments for myeloproliferative neoplasms, a group of rare blood cancers.
Per the agreement with Incyte, QIAGEN will develop a multimodal panel utilizing next-generation sequencing technology to detect clinically relevant gene alterations in hematological malignancies. QIAGEN will also assist with regulatory submissions and market access efforts in the United States, the EU and certain Asia-Pacific regions.
Our Thoughts on INCY Stock
With a new CEO at the helm, INCY is looking to further diversify and strengthen its portfolio.
Incyte’s recent robust rally is positive, and potential label expansion of existing drugs and the launch of new drugs should generate incremental revenues and drive share price gains.
While Jakafi faces competition from the likes of GSK plc’s (GSK - Free Report) Ojjaara in its approved indications, INCY’s efforts to diversify its portfolio are commendable.
GSK posted strong growth in Ojjaara sales in the first half of 2025, driven by continued uptake in the United States and contributions from Europe and International regions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Positive Regulatory Updates Further Boost INCY Stock?
Key Takeaways
Incyte (INCY - Free Report) has put up a stellar performance year to date on the back of better-than-expected quarterly results, and positive pipeline and regulatory updates.
INCY’s Lead Drug Jakafi Maintains Momentum
Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Sales in all indications continue to be strong and should maintain momentum going forward.
Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets. Incyte earns royalties from NVS on sales outside the country.
Opzelura Boosts INCY’s Top Line
The FDA’s approval of the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis (AD), under the brand name Opzelura, has been a significant boost for the company. The drug’s label was recently expanded for mild to moderate AD in non-immunocompromised children two years of age and older.
The drug is also approved for the topical treatment of non-segmental vitiligo in adult and pediatric patients aged 12 years and above. The approval makes Opzelura the first and only topical formulation of a JAK inhibitor approved in the United States. The uptake of Opzelura has been strong, driven by increased patient demand and refills in both atopic dermatitis and vitiligo.
Pipeline/Regulatory Updates Boost INCY Stock
Incyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.
Encouraging uptake of new drugs like Pemazyre, Monjuvi and Tabrecta also contributes to its top-line growth.
The FDA had earlier approved Monjuvi (tafasitamab-cxix) for a new cancer indication.
Monjuvi, in combination with Rituxan (rituximab) and Revlimid (lenalidomide), was approved for the treatment of adult patients with relapsed or refractory follicular lymphoma, a type of slow-growing blood cancer.
The drug is already approved, in combination with Revlimid, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
Incyte gained worldwide exclusive global rights for tafasitamab from MorphoSys AG in February 2024. Tafasitamab is marketed as Monjuvi in the United States and as Minjuvi in the ex-U.S. markets.
The label expansion of the drug should boost sales of the drug.
In May 2025, the FDA approved a label expansion of oncology drug Zynyz (retifanlimab-dlwr), a PD-1 inhibitor. The regulatory body has now approved Zynyz in combination with chemotherapy and as a single agent for the treatment of adult patients with advanced squamous cell carcinoma of the anal canal.
Zynyz is also indicated in the United States for the treatment of adult patients with metastatic or recurrent locally advanced merkel cell carcinoma.
Earlier, INCY’s new global collaboration with Qiagen (QGEN - Free Report) also impressed investors.
The collaboration is aimed at developing a novel diagnostic panel to support INCY’s pipeline of investigational treatments for myeloproliferative neoplasms, a group of rare blood cancers.
Per the agreement with Incyte, QIAGEN will develop a multimodal panel utilizing next-generation sequencing technology to detect clinically relevant gene alterations in hematological malignancies. QIAGEN will also assist with regulatory submissions and market access efforts in the United States, the EU and certain Asia-Pacific regions.
Our Thoughts on INCY Stock
With a new CEO at the helm, INCY is looking to further diversify and strengthen its portfolio.
Incyte’s recent robust rally is positive, and potential label expansion of existing drugs and the launch of new drugs should generate incremental revenues and drive share price gains.
While Jakafi faces competition from the likes of GSK plc’s (GSK - Free Report) Ojjaara in its approved indications, INCY’s efforts to diversify its portfolio are commendable.
GSK posted strong growth in Ojjaara sales in the first half of 2025, driven by continued uptake in the United States and contributions from Europe and International regions.